Antiplatelet Therapy for Percutaneous Coronary Intervention: Something Old and Something New

被引：0
作者：
Gaglia M.A., Jr. [1 ]
机构：
[1] Division of Cardiology, University of New Mexico School of Medicine, 1 University of New Mexico, MSC 10-5550, Albuquerque, 87131, NM
来源：
Current Cardiovascular Risk Reports | 2017年 / 11卷 / 3期
关键词：
Aspirin; Cangrelor; Clopidogrel; Percutaneous coronary intervention; Platelet aggregation inhibitors; Prasugrel; Ticagrelor;
D O I：
10.1007/s12170-017-0533-x
中图分类号：
学科分类号：
摘要：
Purpose of Review: Antiplatelet therapy for patients undergoing percutaneous coronary intervention has rapidly evolved over the last 10 years, often outpacing clinical guidelines. This review appraises recent clinical trials within the context of landmark trials in interventional cardiology, and offers a framework for the integration of recent trials into clinical practice. Recent Findings: This review interprets recent evidence regarding the following: (1) aspirin and the most effective dose; (2) the role of the newer, more potent P2Y12 inhibitors prasugrel, ticagrelor, and cangrelor; (3) an appraisal of the evolving paradigm for duration of dual antiplatelet therapy; and (4) perspective on the role of glycoprotein IIb/IIIa inhibitors in the era of routine and potent P2Y12 inhibition. Summary: The newer and more potent P2Y12 inhibitors, as well as a more nuanced understanding of mainstays of treatment like aspirin, offer the promise of maximizing ischemic benefit and minimizing bleeding in patients undergoing percutaneous coronary intervention. © 2017, Springer Science+Business Media New York.
引用
收藏
相关论文
共 53 条
  • [11] Levine G.N., Bates E.R., Bittl J.A., Brindis R.G., Fihn S.D., Fleisher L.A., Et al., ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, J Am Coll Cardiol, (2016)
  • [12] Aspirin dosing: a patient-centric trial assessing benefits and long-term (ADAPTABLE)
  • [13] Ticagrelor with aspirin or alone in high-risk patients after coronary intervention (TWILIGHT)
  • [14] Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients, BMJ, 324, 7329, pp. 71-86, (2002)
  • [15] Mega J.L., Close S.L., Wiviott S.D., Shen L., Hockett R.D., Brandt J.T., Et al., Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes, Circulation, 119, 19, pp. 2553-2560, (2009)
  • [16] Wallentin L., Varenhorst C., James S., Erlinge D., Braun O.O., Jakubowski J.A., Et al., Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease, Eur Heart J, 29, 1, pp. 21-30, (2008)
  • [17] Wiviott S.D., Braunwald E., McCabe C.H., Montalescot G., Ruzyllo W., Gottlieb S., Et al., Prasugrel versus clopidogrel in patients with acute coronary syndromes, N Engl J Med, 357, 20, pp. 2001-2015, (2007)
  • [18] Jernberg T., Payne C.D., Winters K.J., Darstein C., Brandt J.T., Jakubowski J.A., Et al., Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease, Eur Heart J, 27, 10, pp. 1166-1173, (2006)
  • [19] Trenk D., Stone G.W., Gawaz M., Kastrati A., Angiolillo D.J., Muller U., Et al., A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study, J Am Coll Cardiol, 59, 24, pp. 2159-2164, (2012
  • [20] Valenti R., Marcucci R., Comito V., Marrani M., Cantini G., Migliorini A., Et al., Prasugrel in clopidogrel nonresponders undergoing percutaneous coronary intervention: the RECLOSE-3 study (REsponsiveness to CLOpidogrel and StEnt Thrombosis), JACC Cardiovasc Interv, 8, 12, pp. 1563-1570, (2015)
123456